Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 748 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Foodie Friday: Pumpkin EVERYTHING! October 8, 2021 Political Interests Are A Major Adversary in the War on Women July 6, 2021 Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... December 19, 2023 Study in India Could Make Immunotherapy More Affordable Worldwide November 22, 2022 Load more HOT NEWS Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... ESMO Raises Key Issues on Cancer Prevention and Care at the...
